Trial Profile
A Phase 1/2, Multicenter, Non-Randomized, Open Label Clinical Trial of NPC-08 Implant in Patients Undergoing Surgery for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2013
Price :
$35
*
At a glance
- Drugs Carmustine polifeprosan 20 wafer (Primary)
- Indications Glioblastoma; Glioma
- Focus Therapeutic Use
- 08 Jan 2013 Results have been reported in an Eisai and Nobelpharma media release.
- 05 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Sep 2010 Planned end date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.